Stock Events

Stock Events

Ligand Pharmaceuticals 

$0.050000
48
+$0.00+0% Monday 12:39

Statistics

Day High
0.06
Day Low
0.06
52W High
0.17
52W Low
0.06
Volume
3,200
Avg. Volume
50,000
Mkt Cap
1.2M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
1.19
1.82
2.46
3.09
Expected EPS
2.30301
Actual EPS
N/A

Financials

46.42%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
268.09MRevenue
124.45MNet Income

Analyst Ratings

352.29Average Price Target
The highest estimate is 388.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LGNZZ. It's not an investment recommendation.
Microsoft
13
MSFT
Amazon
10
AMZN
Alphabet
10
GOOGL
Apple
9
AAPL

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap138.91B
Vertex Pharmaceuticals is a competitor due to its focus on creating new drugs and therapies, similar to Ligand's business model of developing or acquiring technologies that help in drug discovery.
Gilead Sciences
GILD
Mkt Cap181.18B
Gilead Sciences competes in the biopharmaceutical space, focusing on antiviral drugs, which overlaps with Ligand's interest in drug development and licensing.
AMGEN
AMGN
Mkt Cap237.52B
Amgen is a direct competitor in the biotech industry, with a broad portfolio of treatments that could compete with Ligand's drug development platforms.
Regeneron Pharmaceuticals
REGN
Mkt Cap85.87B
Regeneron Pharmaceuticals is involved in the discovery, development, and commercialization of pharmaceutical products, directly competing with Ligand's business model.
Biogen
BIIB
Mkt Cap32.03B
Biogen competes with Ligand in the biopharmaceutical sector, especially in the areas of drug discovery and development.
Incyte
INCY
Mkt Cap25.91B
Incyte Corporation operates in the same space as Ligand, focusing on the discovery, development, and commercialization of proprietary therapeutics.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.91B
BioMarin Pharmaceutical targets rare diseases with its genetic disorder treatments, competing with Ligand's focus on novel therapeutics.
Novo Nordisk
NVO
Mkt Cap206.69B
Novo Nordisk, while primarily known for diabetes care, also competes in the biopharmaceutical space, potentially overlapping with Ligand's therapeutic areas.

About

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Show more...
CEO
Todd C. Davis
Employees
47
Country
United States
ISIN
US53220K1732

Listings

STU
DE
LGDN.STU
MU
DE
LGDN.MU
OTC Link
US
LGNZZ
OTC Link
US
LGNXZ

0 Comments

Share your thoughts

FAQ

What is Ligand Pharmaceuticals stock price today?▼
The current price of LGNZZ is $0.05 USD — it has increased by +0% in the past 24 hours. Watch Ligand Pharmaceuticals stock price performance more closely on the chart.
What is Ligand Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Ligand Pharmaceuticals stocks are traded under the ticker LGNZZ.
Is Ligand Pharmaceuticals stock price growing?▼
LGNZZ stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Ligand Pharmaceuticals has showed a -30.23% decrease.
What is Ligand Pharmaceuticals market cap?▼
Today Ligand Pharmaceuticals has the market capitalization of 1.2M
When is the next Ligand Pharmaceuticals earnings date?▼
Ligand Pharmaceuticals is going to release the next earnings report on November 05, 2026.
What were Ligand Pharmaceuticals earnings last quarter?▼
LGNZZ earnings for the last quarter are 2.37 USD per share, whereas the estimation was 2.01 USD resulting in a +17.92% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Ligand Pharmaceuticals revenue for the last year?▼
Ligand Pharmaceuticals revenue for the last year amounts to 268.09M USD.
What is Ligand Pharmaceuticals net income for the last year?▼
LGNZZ net income for the last year is 124.45M USD.
How many employees does Ligand Pharmaceuticals have?▼
As of August 25, 2026, the company has 47 employees.
In which sector is Ligand Pharmaceuticals located?▼
Ligand Pharmaceuticals operates in the Health & Wellness sector.
When did Ligand Pharmaceuticals complete a stock split?▼
The last stock split for Ligand Pharmaceuticals was on November 19, 2010 with a ratio of 1:6.
Where is Ligand Pharmaceuticals headquartered?▼
Ligand Pharmaceuticals is headquartered in SAN DIEGO, United States.